Limited Competition: Cancer Immunotherapy Trials Network (CITN)(UM1)
The summary for the Limited Competition: Cancer Immunotherapy Trials Network (CITN)(UM1) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Limited Competition: Cancer Immunotherapy Trials Network (CITN)(UM1): The purpose of this limited Funding Opportunity Announcement (FOA) is to support the infrastructure to design and conduct multi-institutional Phase I and early Phase II clinical immunotherapy trials for cancer patients, using novel immunomodulatory agents. To realize these goals, the FOA will continue to support the research activities of the Cancer Immunotherapy Trials Network (CITN).
Federal Grant Title: | Limited Competition: Cancer Immunotherapy Trials Network (CITN)(UM1) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Education Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-CA-16-501 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.395 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | January 24th, 2017 |
Original Application Deadline: | January 24th, 2017 |
Posted Date: | November 25th, 2016 |
Creation Date: | November 25th, 2016 |
Archive Date: | February 24th, 2017 |
Total Program Funding: | |
Maximum Federal Grant Award: | $1,500,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | November 25th, 2016 |
- Applicants Eligible for this Grant
- Public and State controlled institutions of higher education - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. Only the current awardee of CITN COSC is eligible to apply. See FOA for eligibility details
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-16-501.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...
- • Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical...
- • Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial ...
- • Assay development and screening for discovery of chemical probes, drugs or immunomodulator...
- • Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed)
- • Breast and Prostate Cancer Data Quality and Patterns of Care Study
- • Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults
- • National Cooperative Drug Discovery Groups for Cancer
- More Grants from the National Institutes of Health
- • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...
- • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...
- • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)
- • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...
- • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...